FDA approves J&J’s Imaavy for generalised myasthenia gravis
Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has received US Food and Drug Administration …
Post
-
-
Investors insist halted biotech IPOs will return in 2025
Investors remain optimistic for a return of biotech IPOs in 2025 despite a market downturn following the announcement of US …
-
GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led …
-
Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution
Biopharmaceutical drug company venture financing witnessed a downturn in Q1 2025, with $6.5bn raised—a 20.2% decline from the $8.1bn raised …
-
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with …
-
Trump’s first 100 days tout US-bound pharma investments amid tariff worries
Pharma companies are looking to shore up manufacturing operations in the US to counter international tariffs, but are also bracing …
-
Donald Trump’s first 100 days: Impact on the healthcare industry
When Donald Trump descended a golden escalator at Trump Tower in New York City in 2015 to announce the launch …
-
Magazine: The GLP-1 shortage is over. What’s next for compounders?
The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to …
-
FDA approves AbbVie’s upadacitinib for giant cell arteritis
The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant …
-
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona Therapeutics has secured US Food and Drug Administration (FDA) approval for Zevaskyn (prademagene zamikeracel), a gene-corrected cell therapy designed …
-
AstraZeneca’s Truqap fails in another Phase III trial
AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to …
-
Impending US tariffs signal uncertain future for global pharma, says GlobalData
In early 2025, US President Donald Trump mentioned the possibility of potential tariffs on foreign-made pharmaceuticals. This threat was raised …
-
Construction begins on MSD’s $1bn biologics centre in Delaware, US
Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The …
-
US tariffs likely to disrupt drug development costs and prices, says GlobalData
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the …
-
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a …
